The new system developed by Professor Chad Mirkin delivers CRISPR machinery more safely and effectively into cells.

Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.

Editas Medicine报告了强劲的财务状况，现金可持续到2027年第二季度。公司在第二季度结束时拥有1.79亿美元现金，足以推进EDIT-401完成人体概念验证及后续研究。此外，资源还分配用于发现工作，包括造血干细胞（HSC）项目的优化和在年底前确定一个额外的靶点。

91%客观缓解率的背后，是CRISPR基因编辑技术对免疫细胞"同族相残"魔咒的彻底打破 在全球细胞治疗领域因CAR-T在B细胞血液肿瘤中的成功而欢呼时，一个顽固的堡垒依然久攻不下——T细胞恶性肿瘤。当患者自身的T细胞已成为“叛军”，如何再用它们制造“平叛军队”？即使造出军队，它们是否会在执行任务前就“自相残杀”？ 美国生物科技公司Wugen用一项突破性的技术设计和1.15亿美元的最新融资，给出了自 ...

2025年9月3日周三，Editas Medicine (NASDAQ:EDIT)在2025年富国银行第20届年度医疗保健会议上发表演讲。该公司宣布了EDIT-401（一种旨在降低LDL胆固醇的基于CRISPR的基因编辑候选药物）的重要里程碑。尽管这种创新治疗方法前景广阔，但该公司仍面临市场竞争和监管审批相关的挑战。 分析师询问了目标患者群体，该公司正考虑难治性群体，如家族性高胆固醇血症(HFH) ...

2013 年，希希，出生在湖南，仅 9 个月大时就被确诊为最严重的 β0/β0 型重度地贫。这意味着他需要终生定期输血和除铁治疗才能维持生命，沉重的医疗负担让他成为“百万宝宝”，也让家庭陷入绝望——寻找全相合造血 干细胞 移植配型难如登天。

CRISPR technology promises to make what was merely a subject of sci-fi into reality, and will completely revolutionize the way we approach medicine.

Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that ...

The most revolutionary technology in medicine today, and perhaps science in general, is CRISPR. It holds vast applications, from curing genetic diseases, detecting and treating cancers, treating ...

Integrated DNA Technologies describes methods that can be used to quantify and characterize off-target editing in gene editing experiments.

The global CRISPR-based gene editing market size is projected to grow from USD 4.46 billion in 2025 to over USD 13.39 billion by 2034, expanding at a CAGR of 13%. Growth is fueled by advancements in ...